Prof. Dr. ŞUAYİB YALÇIN

6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 Kasım - 01 Aralık 2019, cilt.5 Sürdürülebilir Kalkınma

The Role of Radiotherapy /- Chemotherapy in the treatment of Rectal Cancer: Single Center Experience

TİLKİ B., HÜRMÜZ P., CENGİZ M., YILDIZ F., ZORLU A. F., ÖZYİĞİT G., et al.

6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 Kasım - 01 Aralık 2019, cilt.5 Sürdürülebilir Kalkınma

Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).

Alsina M., Tabernero J., Shitara K., Doi T., Dvorkin M., Mansoor W., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37 Sürdürülebilir Kalkınma

Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37

COMBINATION OF OxALIPLATIN, CAPECITABINE,t r a s t u z u m a b a n d c h e m o r a d io t h e r a p y INPATIENTS WITH GASTRIC CANCER

ABALI H., YALÇIN Ş., ÖNAL H. C., DANE F., ÇAKMAK ÖKSÜZOĞLU Ö. B., ÖZDEMİR N., et al.

8 th INTERNATIONALGASTROINTESTINALCANCER CONFERENCE, 7 - 09 Aralık 2018 Sürdürülebilir Kalkınma

Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi

GÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., et al.

2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018 Sürdürülebilir Kalkınma

A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Abali H., Yalcin S., Onal C., Dane F., Oksuzoglu B., Ozdemir N., et al.

Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 18 - 20 Ocak 2018, cilt.36 Sürdürülebilir Kalkınma

Economic Burden of Gastric Cancer in Turkey

BİLİCİ A., GÜMÜŞ M., MALHAN B. S., Öksüz E., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN Ş.

ISPOR 20th Annual European Congress, 4 - 08 Kasım 2017 Sürdürülebilir Kalkınma

Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.

Escobar N. E. I., Luaces P. L., Valdes L. S., Silva C. V., Ramos T. C., Strumberg D., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35 Sürdürülebilir Kalkınma

Beyin Tumorlerinde Serum Peptidomik Analiz

PINAR A., KUTLUK M. T., Mut A. M., KARAHAN S., AKALAN N., YALÇIN Ş., et al.

22. Ulusal Kanser Kongresi, Türkiye, 19 - 23 Nisan 2017

FREQUENCY OF CHEMOTHERAPY INDUCED AMENORRHEA IN WOMEN WITH COLORECTALCANCER

ŞAHİN T., DİZDAR Ö., ÖZDEMİR N., ZENGİN N., ATEŞ Ö., ÇAKMAK ÖKSÜZOĞLU Ö. B., et al.

International Congress on Oncological Sciences, 27 Eylül - 01 Ekim 2017 Sürdürülebilir Kalkınma

A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

Abali H., Yalcin S., Onal H. C., Dane F., Oksuzoglu B., Ozdemir N., et al.

Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 21 - 23 Ocak 2016, cilt.34

Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factors

Goker H., Gunes G., Demiroglu H., Malkan Ü. Y., Haznedaroglu I., Sayinalp N., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

Signet ring cell carcinoma of breast: Single center experience.

AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.

frequency of c Met HGF and HER 2 expression and evaluation of their association with clinicopathological and prognostic factors in gastric cancer

YALÇIN Ş., yetkin y., SÖKMENSÜER C.

gastrointestinal cancers symposium 2015, 15 - 17 Ocak 2015 Sürdürülebilir Kalkınma

Frequency of c-Met, HGF, and HER-2 expression and evaluation of their association with clinicopathologic and prognostic factors in gastric cancer.

YALÇIN Ş., Yildiz Y., SÖKMENSÜER C.

Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 15 - 17 Ocak 2015, cilt.33 Sürdürülebilir Kalkınma

Predictors of outcome in patients with advanced nonseminamatous germ cell testicular tumors.

Yetisyigit T., Babacan N., Urun Y., Seber S., Arpaci E., Clhan S., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (SORAMIC).

Ricke J., Schutte K., Rosmorduc O., Peck-Radosavljevic M., Verslype C., Sangro B., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

Evaluation of the frequency of c-Met and HER2 expressions in gastric carcinoma and their association with clinicopathologic factors

YALÇIN Ş., Yildiz Y., SÖKMENSÜER C.

Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 16 - 18 Ocak 2014, cilt.32

Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results

Ravaud A., Barrios C. H., Alekseev B. Y., Tay M. H., Agarwala S. S., Yalcin S., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31

Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)

Strumberg D., Schultheis B., Ebert M. P., Kerkhoff A., Hofheinz R. D., Behringer D. M., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31 Sürdürülebilir Kalkınma

The impact of adjuvant delayed radiotheraphy (RT) on survival in patients with resected periampullary adenocarcinomas.

Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31

Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study

Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30 Sürdürülebilir Kalkınma

Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.

Yalcin S., Buyukberber S., Yilmaz U., Lee P., Srimuninnimit V., Lin P., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30

Post-Progression Therapies in Patients with Advanced Neuroendocrine Tumors (NET): Analysis From the RADIANT-2 Trial

Hobday T., Becerra C., YALÇIN Ş., Panneerselvam A., Saletan S., Hainsworth J.

76th Annual Scientific Meeting of the American-College-of-Gastroenterology, Washington, Kiribati, 28 Ekim - 02 Kasım 2011, cilt.106

POST-STUDY TREATMENT OPTIONS ARE LIMITED IN PATIENTS WITH ADVANCED NET: ANALYSIS OF POST-PROGRESSION THERAPIES FROM THE RADIANT-2 TRIAL

Peeters M., Becerra C., Panneerselvam A., Saletan S., YALÇIN Ş.

European-Society-for-Medical-Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 22 - 25 Haziran 2011, cilt.22

Serological response to influenza vaccine haematopoetic stem cell transplantation patients

YALÇIN Ş., Kondolot M., Albayrak N., Altas B., Karacan Y., KUŞKONMAZ B. B., et al.

36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Vienna, Avusturya, 21 - 24 Mart 2010, cilt.45 Sürdürülebilir Kalkınma

REGATE: What happens to gastric cancer treatment in the real world?

Ter-Ovanesov M., Bang Y., Wu C., Yalcin S., Roth A., Zalcberg J., et al.

Satellite Symposium on New Horizons for Gastric Cancer held in conjunction with the 8th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 29 Haziran 2006, cilt.17, ss.31 Sürdürülebilir Kalkınma